Study identification

EU PAS number

EUPAS36014

Study ID

50637

Official title and acronym

A non-interventional study to examine patient characteristics and drug utilization patterns in migraine patients treated with prophylactic drugs in Nordic countries

DARWIN EU® study

No

Study countries

Denmark
Finland
Norway
Sweden

Study description

The primary objective was to describe utilization of erenumab among patients with migraine.
The secondary objective was to identify potential comparators for a future erenumab PASS.
The exploratory objectives were 1) to estimate rates of cardiovascular outcomes in patients initiating erenumab or other prophylactic migraine medication, and 2) to describe utilization of erenumab and outcome in pregnancy.

Study status

Finalised
Research institutions and networks

Institutions

University of Bergen Kalfarveien 31, 5018 Bergen, Norway

Contact details

Henrik Toft Sørensen

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Novartis Pharma AG
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)